TICKERNERD
Menu
ANABANABHealthcare · Biotechnology

ANAB Stock Forecast: AnaptysBio, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$58
+4.37% on the day

The 11 Wall Street analysts covering AnaptysBio, Inc. hold a median 12-month price target of $81 — +38.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.7B
Ticker Nerd rank
100 / 100
Median analyst target
$81
Analysts covering
11
Total return, dividends reinvested
1W
+3.3%
1M
−6.5%
YTD
+80.9%
1Y
+339.2%
From 52W high
−16.2%
From 52W low
+352.1%
$13
$70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANAB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AnaptysBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
100 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Quality
97
Issuance
97
Growth
92
Accruals
92
Volatility
85
Momentum
84
Revisions
66
Size
38

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (66): Analysts have, on balance, been cutting their forecasts.

Size (38): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANAB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANAB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150Oct 25Jan 26Apr 26Jul 26ANABHigh $140Median $81Low $70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $70Median $81High $140

The green dot is the last close — the median target sits +38.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 June 2026HC Wainwright & Co.AssumesBuy$95
13 May 2026BarclaysMaintainsOverweight—
13 May 2026UBSMaintainsBuy—
4 May 2026Piper SandlerMaintainsOverweight—
28 Apr 2026Leerink PartnersMaintainsOutperform—
22 Apr 2026BarclaysMaintainsOverweight—
21 Apr 2026UBSMaintainsBuy—
31 Mar 2026Piper SandlerMaintainsOverweight—
30 Mar 2026HC Wainwright & Co.ReiteratesBuy—
17 Mar 2026UBSMaintainsBuy—
12 Mar 2026WedbushMaintainsOutperform—
9 Mar 2026Truist SecuritiesMaintainsHold—
5 Mar 2026StifelMaintainsBuy—
4 Mar 2026BarclaysMaintainsOverweight—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
20 Jan 2026BarclaysMaintainsOverweight—
7 Jan 2026UBSAssumesBuy$20 → $70
17 Dec 2025BarclaysMaintainsOverweight—
11 Dec 2025StifelMaintainsBuy—
24 Nov 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANAB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ANAB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−110.6%
Analysts raising
0
Analysts cutting
4
Fundamentals

AnaptysBio, Inc. (ANAB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−127.2×

Cheaper than 99% of US stocks

Price / sales
7.4×

Cheaper than 18% of US stocks

Price / book
133.2×

Cheaper than 1% of US stocks

EV / EBITDA
40.9×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
−8.0%

Higher than 17% of US stocks

Earnings growth (YoY)
−8.0%

Higher than 27% of US stocks

Gross margin
—
Operating margin
−135.5%

Higher than 12% of US stocks

Net margin
−11.5%

Higher than 19% of US stocks

Returns & dividend
Return on equity
−114.6%

Higher than 11% of US stocks

Return on assets
6.8%

Higher than 84% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ANAB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANABAnaptysBio, Inc.$1.7B
100
SNDXSyndax Pharmaceuticals, Inc.$1.7B
66
AVLNAvalyn Pharma, Inc.$1.7B
1
ZYMEZymeworks, Inc.$1.8B
70
XNCRXencor, Inc.$1.7B
82
NTLAIntellia Therapeutics, Inc.$1.7B
53
RXRXRecursion Pharmaceuticals, Inc.$1.6B
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AnaptysBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANAB news & analysis

AnaptysBio: The Royalty Waterfall Is About To Reverse

Seeking Alpha · 29 July 2026positive

AnaptysBio has repositioned as a focused royalty management company, with its value primarily tied to Jemperli royalties from GSK. The company now operates virtually with a 95% targeted EBIT margin and over $140M net cash, having eliminated its prior R&D burn.

Why it matters — ANAB watchers would care because once the Sagard obligation is paid by mid-2027, the company will retain high-margin, growing royalty streams that escalate with Jemperli sales.

FAQ

Frequently asked questions about ANAB stock

What is the ANAB stock price forecast for 2026-2027?

The 11 Wall Street analysts covering AnaptysBio, Inc. have a median 12-month price target of $81, with estimates ranging from $70 to $140. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANAB stock a buy right now?

Of the 11 analysts covering AnaptysBio, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AnaptysBio, Inc. 100 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANAB?

As at 15 Aug 2026, AnaptysBio, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will ANAB stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +38.5% from the last close, and Ticker Nerd's factor model ranks AnaptysBio, Inc. 100 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANAB stock forecast for 2030?

No analyst covering AnaptysBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $140 over the next 12 months.

How has ANAB stock performed over the past year?

AnaptysBio, Inc. returned +339.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AnaptysBio, Inc. do?

AnaptysBio Inc. is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases.

What is the latest news on ANAB?

The most recent item we track (Seeking Alpha, 29 July 2026): "AnaptysBio: The Royalty Waterfall Is About To Reverse". AnaptysBio has repositioned as a focused royalty management company, with its value primarily tied to Jemperli royalties from GSK. The company now operates virtually with a 95% targeted EBIT margin and over $140M net cash, having eliminated its prior R&D burn.

Company

About AnaptysBio, Inc.

AnaptysBio Inc. is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. It advances antibody-based drug candidates that modulate immune pathways, including rosnilimab, a PD-1 agonist and pathogenic T cell depleter studied in rheumatoid arthritis; ANB033, a CD122 antagonist in trials for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator; and ANB032, a BTLA agonist for atopic dermatitis. The company has discovered and out-licensed therapeutic antibodies through financial collaborations, such as Jemperli (dostarlimab-gxly), a PD-1 antagonist to GSK for oncology indications, and imsidolimab, an IL-36 receptor antagonist to Vanda Pharmaceuticals for generalized pustular psoriasis. These partnerships provide eligibility for milestone payments and royalties. AnaptysBio Inc. maintains biopharma operations centered on internal clinical programs alongside its royalty-generating assets. Headquartered in San Diego, California, since 2005, it plays a key role in the immunology sector by targeting immune cell modulation to address unmet needs in autoimmune conditions.

CEO Mr. Daniel R. Faga · 104 employees · United States · https://www.anaptysbio.com